26 completed, 15 recruiting, 11 unknown, 4 active not recruiting. 59 Phase 2, 9 Phase 1, 7 Phase 3.
Follow Language Disorders: new trials by email Literature Review of Language Disorders trials Research Report on Language Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Superiority Trial of Aphasia-focused Rehabilitation With tDCS Stimulation tDCS - Aphasia, Broca's Aphasia | Phase 2 / Phase 3 | Recruiting | University of South Carolina | 130 | 2026-07-14 | 2026-07-21 |
| Addressing Treatment Nonresponders VAULT Phase 6 - Language Development Disorders | Phase 2 | Not yet recruiting | University of Arizona | 16 | 2026-06-01 | 2025-07-30 |
| Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter Psilocybin, Speech therapy - Stuttering | Phase 2 | Recruiting | NYU Langone Health | 25 | 2026-05-07 | 2026-11-10 |
| Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder Lumateperone (ITI-007), Placebo Tablet or Capsule - Stuttering, Adult | Phase 2 | Recruiting | CSTrials Inc. | 24 | 2026-04-18 | 2026-07-29 |
| Exploratory Evaluation of the Digital Therapeutic Device Zenicom for Subacute Stroke Aphasia Zenicog, Conventional Speech Therapy - Aphasia, Stroke | Phase 2 | Recruiting | Seoul National University Bundang Hospital | 20 | 2025-12-10 | 2026-02-10 |
| Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia Neflamapimod, Placebo - Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Phase 2 | Active not recruiting | EIP Pharma Inc | 20 | 2025-10-02 | 2026-07-06 |
| Comparing Traditional Semantic Feature Analysis (tSFA) and Semantic Feature Analysis + Metacognitive Strategy Training (SFA+MST) Semantic Feature Analysis (traditional), Semantic Feature Analysis + Metacognitive Strategy Training - Aphasia, Aphasia Following Cerebral Infarction | Phase 2 | Recruiting | Teachers College, Columbia University | 40 | 2025-07-28 | 2026-06-25 |
| A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound - Central Auditory Processing Disorder, Hearing Impaired (Partially) | Phase 1 / Phase 2 | Recruiting | University of Colorado, Denver | 344 | 2025-03-31 | 2026-04-30 |
| Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia Transcranial Magnetic Stimulation (TMS), Speech-Language Therapy (SLT) - Aphasia, Stroke | Phase 2 | Recruiting | University of Pennsylvania | 24 | 2025-02-11 | 2026-03-05 |
| Lateral Cord Magnetic Stimulation For Refractory Spastic Cerebral Palsy Magnetic Spinal Stimulation - Spastic Cerebral Palsy, Dysarthria | Phase 2 / Phase 3 | Unknown | Sociedad Argenttina de Neuromodulación | 20 | 2024-11-18 | 2023-11-21 |
| Communication Bridge 3 Study Communication Bridge™, Evidence-Based Impairment Focused - Primary Progressive Aphasia | Phase 2 | Recruiting | University of Chicago | 200 | 2024-08-23 | 2026-06-01 |
| Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia Transcranial Magnetic Stimulation (TMS), Modified Constraint Induced Language Therapy (mCILT) - Stroke, Aphasia | Phase 2 | Recruiting | University of Pennsylvania | 63 | 2024-08-01 | 2026-06-18 |
| Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia Active tDCS + Language Therapy, Sham tDCS + Language Therapy - Primary Progressive Aphasia, Logopenic Progressive Aphasia | Phase 2 | Recruiting | Johns Hopkins University | 180 | 2024-02-13 | 2026-05-05 |
| Adaptive Trial Scheduling in Naming Treatment for Aphasia Adaptive Spacing Condition, High-Item Non-Adaptive Spacing Condition, Low-Item Non-Adaptive Spacing Condition - Aphasia, Stroke | Phase 2 | Recruiting | University of Pittsburgh | 32 | 2023-12-06 | 2025-12-11 |
| Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia Accuracy-maximized condition, Effort-maximized condition, Effort-accuracy balanced condition - Aphasia, Stroke | Phase 2 | Recruiting | University of Pittsburgh | 30 | 2023-11-27 | 2026-04-13 |
| A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101 - Frontotemporal Dementia, FTD | Phase 1 / Phase 2 | Recruiting | AviadoBio Ltd | 18 | 2023-08-30 | 2026-08-13 |
| The Effect of Prior Learning on Word Learning VAULT Phase 4 - Language Development Disorders | Phase 2 | Completed | University of Arizona | 22 | 2023-06-01 | 2025-06-27 |
| Nabilone for Agitation in Frontotemporal Dementia Nabilone, Placebo - Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant | Phase 2 | Terminated | Simon Ducharme, MD | 3 | 2023-03-07 | 2026-07-28 |
| Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA) Transcranial Direct Current Stimulation (tDCS), Word-Naming Activity - Primary Progressive Aphasia | Phase 2 | Completed | NYU Langone Health | 11 | 2022-12-24 | 2024-09-19 |
| Escitalopram and Language Intervention for Subacute Aphasia Escitalopram 10mg, Placebo, Computer-delivered naming treatment - Aphasia, Stroke | Phase 2 | Recruiting | Johns Hopkins University | 88 | 2021-07-18 | 2026-09-03 |
Showing 20 of 59. Sign in to see all of them.
Aphasia (24) · Stroke (16) · Aphasia, Primary Progressive (8) · Language Development Disorders (7) · Stuttering (7) · Communication Disorders (5) · Dementia (5) · Dyslexia (5) · Frontotemporal Dementia (5) · Language (5) · Anomia (4) · Aphasia, Broca (4) · Autism Spectrum Disorder (4) · Speech Disorders (4)
Pathological Conditions, Signs and Symptoms (59) · Signs and Symptoms (59) · Neurobehavioral Manifestations (58) · Neurologic Manifestations (58) · Nervous System Diseases (57) · Communication Disorders (54) · Speech Disorders (38) · Brain Diseases (26) · Central Nervous System Diseases (25) · Mental Disorders (24) · Neurodevelopmental Disorders (18) · Cardiovascular Diseases (16) · Cerebrovascular Disorders (16) · Vascular Diseases (15)
Transcranial Direct Current Stimulation (5) · Leucovorin (3) · Speech Therapy (2) · Therapeutics (2) · Transcranial Magnetic Stimulation (2) · ecopipam (2) · Capsules (1) · Clemastine (1) · Commerce (1) · Escitalopram (1) · Fluoxetine (1) · Language Therapy (1) · Lovastatin (1) · Methods (1) · Nerve Growth Factor (1)
Southwest Autism Research & Resource Center (3) · University of Pennsylvania (3) · Johns Hopkins University (2) · NYU Langone Health (2) · University of Arizona (2) · University of Pittsburgh (2) · University of South Carolina (2) · University of Sydney (2) · Ain Shams University (1) · AviadoBio Ltd (1) · CSTrials Inc. (1) · Charite University, Berlin, Germany (1) · Charité Neurocure AG Flöel (1) · Climb Up Kids (1) · EIP Pharma Inc (1)
United States (41) · Canada (6) · Germany (4) · Australia (2) · Italy (2) · Sweden (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Egypt (1) · India (1) · Netherlands (1) · Norway (1) · Poland (1) · Russia (1)
H. Branch Coslett, MD (3) · Richard E Frye, MD, PhD (3) · Mary Alt, PhD (2) · William Evans, PhD (2) · Abhishek Datta, Ph.D (1) · Achim Klug, PhD (1) · Agnes Floeel, Prof MD (1) · Agnes Floel, MD (1) · Alessandro Martorana, MD, PhD (1) · Alexander A Ostanin, MD, PhD (1) · Ann Kaiser, PhD (1) · Argye Hillis-Trupe, MD (1) · Atul R Mahableshwarkar, MD, DFAPA (1) · Bruce Crosson, PhD (1)
PMID 10917410, PMID 12849360, PMID 15026214, PMID 15212606, PMID 15328899, PMID 20075648, PMID 21636820, PMID 23106988, PMID 24434529, PMID 25267381, PMID 28738099, PMID 29357099, PMID 30128538, PMID 31369655, PMID 32878377, PMID 33642973, PMID 33643204, PMID 34941929, PMID 40809903, PMID 42161555
R01DC015642 (2), R01DC019325 (2), 2023 (1), P50DC014664 (1), R01AG055425 (1), R01AG075111 (1), R01DC007387 (1), R01DC016321 (1), R01DC016800 (1), R01HD088528 (1), R01HD089474 (1), R15DC009027 (1), R21DC021833 (1), R44NS092144 (1), U01DC011739 (1)